C. Jeffrey Dekker - Dec 8, 2022 Form 4 Insider Report for ARCA biopharma, Inc. (ABIO)

Role
Chief Financial Officer
Signature
/s/ C. Jeffrey Dekker
Stock symbol
ABIO
Transactions as of
Dec 8, 2022
Transactions value $
$0
Form type
4
Date filed
12/9/2022, 03:30 PM
Previous filing
Dec 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction ABIO Common Stock Award $0 +40 K $0.00 40 K Dec 8, 2022 Direct F1

Explanation of Responses:

Id Content
F1 Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested).